 |
|
Risk Factors for Neuroleptic Malignant SyndromeA Case-Control Study
Paul E. Keck, Jr, MD;
Harrison G. Pope, Jr, MD;
Bruce M. Cohen, MD, PhD;
Susan L. McElroy, MD;
Andrew A. Nierenberg, MD
Arch Gen Psychiatry. 1989;46(10):914-918.
Abstract
• A number of risk factors have been proposed for the development of neuroleptic malignant syndrome, but these have not been subjected to controlled study. To address this problem, we performed a case-control study comparing 18 patients with neuroleptic malignant syndrome and 36 matched neuroleptictreated control patients with no known history of the syndrome to identify potential risk factors. Patients with neuroleptic malignant syndrome displayed significantly greater psychomotor agitation, received significantly higher doses of neuroleptics at greater rates of dosage increase, and received a greater number of intramuscular injections than controls.
Author Affiliations
From the Biological Psychiatry Laboratory and Clinical Research Center, Laboratories for Psychiatric Research, Mailman Research Center, McLean Hospital, Belmont, Mass, and Harvard Medical School, Boston, Mass.
Footnotes
Accepted for publication February 13, 1989.
Presented at the 27th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 13, 1988.
Reprint requests to McLean Hospital, 115 Mill St, Belmont, MA 02178 (Dr Keck).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Neuroleptic Malignant Syndrome Versus Serotonin Syndrome: The Search for a Diagnostic Tool
Sokoro et al.
The Annals of Pharmacotherapy 2011;45:e50-e50.
ABSTRACT
| FULL TEXT
Neuroleptic Malignant Syndrome: A Review for Neurohospitalists
Berman
The Neurohospitalist 2011;1:41-47.
ABSTRACT
| FULL TEXT
Neuroleptic malignant syndrome: a neuroimmunologic hypothesis
Anglin et al.
CMAJ 2010;182:E834-E838.
FULL TEXT
Use of psychotropic medication in seven English psychiatric intensive care units
Brown et al.
The Psychiatrist 2010;34:130-135.
ABSTRACT
| FULL TEXT
Acute Dystonic Reaction and the Neuroleptic Malignant Syndrome
White
Journal of Pharmacy Practice 2005;18:175-187.
ABSTRACT
A Double-blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in Schizophrenia
Breier et al.
Arch Gen Psychiatry 2002;59:441-448.
ABSTRACT
| FULL TEXT
Neuroleptic malignant syndrome
Adnet et al.
Br J Anaesth 2000;85:129-135.
FULL TEXT
Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert et al.
Arch Gen Psychiatry 1995;52:173-188.
ABSTRACT
The Clinical Significance of Serial Creatine Phosphokinase Estimations in Acute Ward Admissions
Wilhelm et al.
Aust N Z J Psychiatry 1994;28:453-457.
ABSTRACT
|
